In light of the observation that the MST2 pathway participates in mediating cell death in PLX4032-sensitive mutant BRAF melanoma cells, we wanted to know if this pathway is associated with the acquisition of resistance to BRAFi. The gene discussed is STK3; the disease is melanoma.